This week, we will discuss the (probably) final story in the timing of RRT in AKI story. We discussed ELAIN, AKIKI and STARRT AKI. Early dialysis is not a good idea. But how late can you go? Let’s see with AKIKI-2
This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.
This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.
This week, we will discuss the VALIANT study, pegcetacoplan in C3G and IC MPGN.
2025 was rich in successful stories. Here are the top 10 that impressed our audience.